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A ntibiotics are among the most frequently prescribed agents in hospitalized patients and account for up to half of all hospital drug expenditures. Yet, despite the approval and marketing of new antibiotics each year by the Food and Drug Administration, infections remain a major cause of morbidity and mortality in the United States and are responsible for approximately one-third of all hospital admissions. Effectively managing and treating infections has been confounded by an increase in resistance patterns among pathogenic bacteria-particularly those causing nosocomial and surgical-site infections. Inappropriate antibiotic use has been recognized as a major contribution to the development of bacterial resistance. Use of the wrong antibiotic, suboptimal levels, or duration encourages the development of such resistance.
In the acute care setting, several intervention strategies have been identified in promoting rational and effective antimicrobial use while reducing bacterial resistance, [1] [2] [3] [4] including restrictive formularies, antibiotic utilization reviews, pre-authorization protocols, standardized protocols, computerized support algorithms, and multidisciplinary antimicrobial teams. Although no one method is the sole answer to this dilemma, the role of the pharmacist as a val-ued contributor in antimicrobial use and surveillance has been recognized. Typical responsibilities of the infectious disease pharmacist may vary between institutions but a literature review promotes the following activities:
• Provision of advice on the management of antibiotic therapy in individual cases; • Education and training for other health care professionals on prudent antibiotic use within hospital guidelines and policies; • A liaison between the microbiology and pharmacy departments (with regards to formulary, susceptibility testing, and monitoring of antibiotic levels); • Involvement in the development and maintenance of antibiotic guidelines, participation in formulary decisions regarding antibiotics; and • Monitoring antibiotic use within the health care system. The use of antibiotic therapy teams has been suggested as one method to improve outcomes in hospitalized patients who receive intravenous antibiotics and results in substantial cost savings. 3 Such teams typically consist of an infectious disease physician, a clinical microbiologist, and an infectious disease pharmacist. However, there is growing evidence that has also documented the impact of pharmacists as providers of antibiotic therapy intervention. 1, 2 Recently, an evaluation of pharmacist-managed antimicrobial prophylaxis in Medicare-surgical patients from 806 hospitals in the United States revealed that the involvement of pharmacists resulted in a significant improvement in clinical and economic outcomes. Specifically, hospitals without pharmacist-managed antimicrobial prophylaxis in surgical patients demonstrated significant increases in surgical-site infections (34.3%), mortality rates (52.06%), length of hospital stay (10.21%), total Medicare charges (3.1%), mean drug charges (7.24%), and mean laboratory charges (7.24%). 2 Another report has described the substantial economic benefit of on-call infectious disease pharmacists in ensuring appropriate alternatives to restricted-use antibiotics-per the Pharmacy and Therapeutics Committee. 1 Hospital Pharmacy is interested in providing a forum to discuss the increasing role of pharmacists in the effective management of infection in the health care system. Share your experiences, ideas, and questions with us at hospitalphar-macy@drugfacts.com.
